Discussion
obesity, GI cancers, CRC, cancer, GI cancer, overweight
OBESITY, OBESE, CANCER, GI CANCER, DYSFUNCTION, SECONDARY, INFLAMMATORY RESPONSE
In this cohort study, we found that overweight and obese BMI at different ages and change in BMI over time may be associated with increased risk of GI cancers. We further found that aspirin use 3 or more times per week did not modify this association. Aspirin use for cancer prevention has been well supported by decades of epidemiological evidence. Previous secondary analysesObesity results from the buildup and storage of white adipose tissue, or fat. Adipose cells can induce the inflammatory response and promote immune cell dysfunction through the secretion of adipokines and proinflammatory cytokines, leading to further downstream mechanistic dyregulation.As found in the current study, obesity may alter the cancer preventive effect of aspirin. Our results indicate that individuals with overweight and obese BMIs had an increased risk of CRC and noncolorectal GI cancer with aspirin use 3 or more times per week, suggesting that aspirin may not be efficacious for prevention in overweight or obese states. The ability of aspirin to protect against GI cancers may be blunted in people with obesity because of inadequate dosing.